Education
Timely Topics in Transplantation Webinar Series
September 27, 2017
Polling questions and answers are available for download here.
Speaker: Massimo Mangiola, PhD • University of Pittsburgh Medical Center
Moderator: Julie Yabu, MD • UCLA
After participating in this webinar, the learner will be able to:
- Describe epitopes in the context of transplantation.
- Discuss the importance of epitopes in HLA compatiblity and optimizing graft outcome.
- Summarize how to potentially use "epitope tools" in HLA antibody analysis and matching of donors and recipients pairs.
June 21, 2016
Speaker: Robert Ettenger, MD • UCLA Center for Health Science
Moderator: Vikas Dharnidharka, MD • Washington University
After participating in this webinar, the learner will be able to:
- Understand the measures that can be taken before, during and after the first transplant to promote the success of the second transplant
- Identify the appropriate immunological, psychological,and technical steps that should be taken to help assure an optimal outcome
- Describe the peri- and post-transplant care, including immunosuppression, that are necessary to obtain the best results
April 21, 2015
Atul Humar, MD • University Health Network-University of Toronto
Camille Kotton, MD • Massachusetts General Hospital
Raymund Razonable, MD • Mayo Clinic
Moderated by Shirish Huprikar, MD • Icahn School of Medicine at Mount Sinai
Read the Q&A that wasn't answered during webinar
Free to AST members: $25 fee is waived upon logging in during the checkout process.
Dr. Kotton will describe the importance of prevention, and the various methods of preventing CMV, including; universal prophylaxis, preemptive therapy, and a hybrid approach, along with the merits and downfalls of each approach. Dr. Razonable will review the current recommendations for the treatment of cytomegalovirus infection and disease in transplant recipients, and discuss antiviral drugs in the pipeline that may be useful for the treatment of drug-resistant infections. Dr. Humar will explain how measurements of host immune response to CMV can be used to predict the risk of CMV reactivation in different settings, and how prevention and treatment strategies might be refined with the use of immune monitoring tools.
After participating in this webinar, the learner will be able to:
- Discuss the importance of CMV prevention, along with the various approaches used for optimal prevention
- Explain the standard treatment for CMV infection and disease in transplant recipients and discuss novel antiviral drugs
- Describe the potential for using immune monitoring tools to refine and improve prevention and treatment strategies
Dr. Kotton will describe the importance of prevention, and the various methods of preventing CMV, including; universal prophylaxis, preemptive therapy, and a hybrid approach, along with the merits and downfalls of each approach. Dr. Razonable will review the current recommendations for the treatment of cytomegalovirus infection and disease in transplant recipients, and discuss antiviral drugs in the pipeline that may be useful for the treatment of drug-resistant infections. Dr. Humar will explain how measurements of host immune response to CMV can be used to predict the risk of CMV reactivation in different settings, and how prevention and treatment strategies might be refined with the use of immune monitoring tools.
Objectives:
- Discuss the importance of CMV prevention, along with the various approaches used for optimal prevention
- Explain the standard treatment for CMV infection and disease in transplant recipients and discuss novel antiviral drugs
- Describe the potential for using immune monitoring tools to refine and improve prevention and treatment strategies
October 23, 2013
Free to AST members: $25 fee is waived upon logging in during the checkout process.
What You'll Learn:
- Appreciate highlights of updated ID COP Guidelines published in 2013
- Appraise novel additions to ID COP Guidelines published in 2013
- Review Updated International Consensus Guidelines on the Management of Cytomegalovirus in Solid-Organ Transplantation
Click here to download additional questions that were answered offline by Dr. Camille Kotton.
March 31, 2015
Peter Heeger, MD • Icahn School of Medicine at Mount Sinai
Moderated by Leonardo Riella, MD, PhD • Brigham and Women's Hospital
Free to AST members: $25 fee is waived upon logging in during the checkout process.
The goal of this webinar is to describe the available data on pre- and post-transplant immune monitoring and how incorporating specific tests may help us diagnose, predict, and better treat our transplant recipients.
After participating in this webinar, the learner will be able to:
- Summarize the current most promising and best tested urine and peripheral blood, molecular, and cellular assays available for risk assessment following transplantation
- Detail the utility, pitfalls and limitations of currently available assays
- Propose future directions and trial designs required to develop and validate immune monitoring tools for clinical use
The goal of this webinar is to describe the available data on pre- and post-transplant immune monitoring and how incorporating specific tests may help us diagnose, predict, and better treat our transplant recipients.
Objectives:
- Summarize the current most promising and best tested urine and peripheral blood, molecular, and cellular assays available for risk assessment following transplantation
- Detail the utility, pitfalls and limitations of currently available assays
- Propose future directions and trial designs required to develop and validate immune monitoring tools for clinical use
October 16, 2013
Free to AST members: $25 fee is waived upon logging in during the checkout process.
What You'll Learn:
- Summarize the major features of the 2013 Banff Conference on Allograft Pathology, held from August 19-23 in Comandatuba, Brazil
- Review the findings of the current Banff Working Groups that were presented at the conference
- Present the newly revised Banff Classification for antibody-mediated rejection in renal allografts, including the rationale for the revisions and the process involved in reaching a consensus on these
- Introduce the three new Banff Working Groups that have been formed as a result of presentations and discussions at the conference
Click here to download additional questions that were answered offline by Dr. Mark Haas.
March 17, 2015
Norah Terrault MD, MPH • University of California, San Francisco
Moderated by Robert Brown, MD, MPH • Columbia University Medical Center
Free to AST members: $25 fee is waived upon logging in during the checkout process.
The diagnosis of chronic hepatitis C has been considered a relative or absolute contraindication for non-liver transplantation in the past, due to concerns of liver disease progression post-transplantation and a lack of safe and effective therapies. The recent availability of interferon-free, all-oral, antiviral drug combinations to treat of chronic hepatitis C provides an opportunity to revise management algorithms to optimize the care of non-liver transplant candidates and recipients.
After participating in this webinar, the learner will be able to:
- Describe the components of the new HCV all-oral combinations, the role of ribavirin, and anticipated rates of HCV eradication with treatment
- Summarize the safety data of new HCV therapies as it pertains to non-liver transplant candidates and recipients, including key drug-drug interactions (HCV antivirals and immunosuppressive drugs)
- Evaluate the pros and cons of HCV treatment pre versus post-transplantation, including considerations related to use of anti-HCV positive donors
The diagnosis of chronic hepatitis C has been considered a relative or absolute contraindication for non-liver transplantation in the past, due to concerns of liver disease progression post-transplantation and a lack of safe and effective therapies. The recent availability of interferon-free, all-oral, antiviral drug combinations to treat of chronic hepatitis C provides an opportunity to revise management algorithms to optimize the care of non-liver transplant candidates and recipients.
Objectives:
- Describe the components of the new HCV all-oral combinations, the role of ribavirin, and anticipated rates of HCV eradication with treatment
- Summarize the safety data of new HCV therapies as it pertains to non-liver transplant candidates and recipients, including key drug-drug interactions (HCV antivirals and immunosuppressive drugs)
- Evaluate the pros and cons of HCV treatment pre versus post-transplantation, including considerations related to use of anti-HCV positive donors
February 17, 2015
David Serur, MD • New York Presbyterian Weill Cornell
Elisa Gordon, PhD, MPH • Northwestern University
Catherine Garvey, RN, BA, CCTC • University of Minnesota Health
Free to AST members: $25 fee is waived upon logging in during the checkout process.
The long-term acceptance of living donor transplantation has been based on a combination of excellent recipient outcomes and belief that in actuarial terms, there is no increased risk of living with one kidney. However, recent studies have raised controversy and concerns regarding the long-term risks of CKD in kidney donors. How do we interpret these findings? How do we evaluate and when do we clear donors with pre-existing medical conditions like hypertension, obesity, kidney stones, etc., and convey divergent opinions to patients? Comprehensive donor consent remains at the core of this process. Though perceived as challenging existing assumptions, the disclosure of new data will enable a better understanding of the risks so that potential living donors can make a more meaningful, informed decision.
After participating in this webinar, the learner will be able to:
- Distinguish between 'low risk donors' and medically complex living donors
- Evaluate the meanings of new studies regarding donor risk
- Refine the current informed consent process in light of the evolving data
The long-term acceptance of living donor transplantation has been based on a combination of excellent recipient outcomes and belief that in actuarial terms, there is no increased risk of living with one kidney. However, recent studies have raised controversy and concerns regarding the long-term risks of CKD in kidney donors. How do we interpret these findings? How do we evaluate and when do we clear donors with pre-existing medical conditions like hypertension, obesity, kidney stones, etc., and convey divergent opinions to patients? Comprehensive donor consent remains at the core of this process. Though perceived as challenging existing assumptions, the disclosure of new data will enable a better understanding of the risks so that potential living donors can make a more meaningful, informed decision.
Objectives:
- Distinguish between “low risk donors” and medically complex living donors.
- Evaluate the meanings of new studies regarding donor risk.
- Refine the current informed consent process in light of the evolving data.
February 10, 2015
Peter Reese, MD, MSCE • University of Pennsylvania
John Friedewald, MD • Northwestern Medicine
Moderated by: Jason Wertheim, MD, PhD • Northwestern University
Free to AST members: $25 fee is waived upon logging in during the checkout process.
The debate over the appropriateness of combined liver and kidney transplants was stoked by the introduction of the MELD system and continues today as the waiting list for kidney alone candidates continues to grow. This education session will feature a review of the current data and experience with combined liver and kidney transplantation and will explore the controversial topics of when to allocate a kidney to candidates with liver failure and acute kidney injury.
After participating in this webinar, the learner will be able to:
1. Describe the current policies at UNOS regarding simultaneous liver-kidney allocation
2. Explain data related to outcomes for liver transplant candidates with kidney injury
3. Summarize arguments and ethics surrounding the development of new allocation policies for simultaneous liver-kidney transplantation
Free to AST members: $25 fee is waived upon logging in during the checkout process.
The debate over the appropriateness of combined liver and kidney transplants was stoked by the introduction of the MELD system and continues today as the waiting list for kidney alone candidates continues to grow. This education session will feature a review of the current data and experience with combined liver and kidney transplantation and will explore the controversial topics of when to allocate a kidney to candidates with liver failure and acute kidney injury.
After participating in this webinar, the learner will be able to:
1. Describe the current policies at UNOS regarding simultaneous liver-kidney allocation
2. Explain data related to outcomes for liver transplant candidates with kidney injury
3. Summarize arguments and ethics surrounding the development of new allocation policies for simultaneous liver-kidney transplantation
January 20, 2015
Jon Kobashigawa, MD • Cedars-Sinai Heart Institute
Matt Morrell, MD • University of Pittsburgh School of Medicine
Moderated by Julie Yabu, MD • Stanford University
Free to AST members: $25 fee is waived upon logging in during the checkout process.
Explore the diagnosis and treatment strategies, including the role of desensitization, in lung and heart transplantation. Discuss challenges and avenues for further research and investigation.
After participating in this webinar, the learner will be able to:
- Describe how to diagnose antibody-mediated rejection in lung and heart transplant recipients.
- Evaluate and review the desensitization strategies currently used in lung and heart transplant candidates and recipients.
- Summarize the different treatment approaches for treatment of antibody-mediated rejection.
Free to AST members: $25 fee is waived upon logging in during the checkout process.
Explore the diagnosis and treatment strategies, including the role of desensitization, in lung and heart transplantation. Discuss challenges and avenues for further research and investigation.
After participating in this webinar, the learner will be able to:
- Describe how to diagnose antibody-mediated rejection in lung and heart transplant recipients.
- Evaluate and review the desensitization strategies currently used in lung and heart transplant candidates and recipients.
- Summarize the different treatment approaches for treatment of antibody-mediated rejection.